KRTX - Karuna Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Karuna Therapeutics, Inc.

33 Arch Street
Suite 3110
Boston, MA 02110
United States
857-449-2244
http://www.karunatx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven M. Paul M.D.CEO, Pres & Chairman312.99kN/A1951
Dr. Andrew Craig MillerCo-Founder & COO462.61kN/A1981
Dr. Stephen K. BrannanChief Medical Officer419.71kN/A1957
Dr. Troy A. IgnelziChief Financial OfficerN/AN/A1968
Dr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.

Corporate Governance

Karuna Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.